Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions. Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-24 8:26 AM EDT | Red Light Holland Corp.
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks 69% of participants fell below clinical thresholds for anxiety and depression after second treatment Research builds on prior studies utilizing Filament's botanica
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-20 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global cl
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-07 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate us
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-01 9:20 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstandin
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-23 8:15 AM EDT | Red Light Holland Corp.
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Li
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-18 8:15 AM EDT | Red Light Holland Corp.
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-11 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-10 4:40 PM EDT | Red Light Holland Corp.
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development ("R&D") initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experie
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-03 8:00 AM EST | Red Light Holland Corp.
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Nutravisor Inc. ("Nutravisor"), dated January 19, 2026, pursuant to which the parties have agreed to complete a business combination involving a "three-cornered" amalgamation of
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-01-19 5:28 PM EST | Entheon Biomedical Corp.
Entheon Announces Letter of Intent with Nutravisor Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding Letter of Intent (the "LOI") dated December 18, 2025, with Nutravisor Inc. ("Nutravisor") whereby Entheon will acquire all of the issued and outstanding common shares of Nutravisor (the "Proposed Transaction"). Upon completion of the Proposed T
Biotechnologies, Cannabis, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2025-12-22 9:30 AM EST | Entheon Biomedical Corp.
Red Light Holland Reports Second Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announces its financial and operat
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2025-12-01 4:30 PM EST | Red Light Holland Corp.
Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives Second, Larger 5kg Psilocybin Shipment via USA Controlled Substances Import Permit
Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws is excited to announce that it has, f
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2025-11-19 7:45 AM EST | Red Light Holland Corp.
Quinsam Reports Q3/2025 Results
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing its Q3/2025 results, with net income of $0.1 million ($0.00 per share basic, $0.00 fully diluted) versus net income of $1.2 million ($0.01 per share basic, $0.01 fully diluted) in Q3/2024. Investors can access the Company's full financial statements on sedarplus.ca. "While our performance
Services bancaires / financiers, Cannabis, Cultivateurs de cannabis, Fournisseurs de services auxiliaires liés au cannabis
2025-11-13 7:30 AM EST | Quinsam Capital Corporation
Red Light Holland's Wholly Owned Subsidiary Happy Caps Expands Safeway Partnership to 123 Stores Across the U.S. Pacific Northwest, in Time for American Thanksgiving
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce a major U.S. retail expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farm ("Happy Caps") with Albertso
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2025-11-11 8:39 AM EST | Red Light Holland Corp.
Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon"). Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price
Biotechnologies, Produits ménagers / de consommation / cosmétiques, Santé, Fournisseurs de services auxiliaires liés au cannabis
2025-11-03 7:07 AM EST | Britannia Life Sciences Inc